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I. INTRODUCTION
[1] Perhaps nothing permeates modern American society as much as
prescription drugs. Evidence of this exists not just in television and
magazine ads extolling the promises of Viagra and Nexium, but also in a
few statistics. First, forty-six percent of Americans use at least one
prescription drug daily. 1 Further, in 2001, 3.1 billion prescriptions were
issued in the United States at a cost of $132 billion. 2 That amount is
projected to increase to $414 billion by 2014. 3 Such numbers explain the
intensity of the recent political and legal debates surrounding prescription
drugs, such as the importation of American pharmaceuticals from Canada
and the issuance of prescriptions online without visiting a physician. 4
During the 2004 presidential campaign, President Bush touted his
Medicare Modernization Act, a significant component of which concerned
*

Jeff Todd is a third-year student at the University of Texas School of Law. A former
professor of professional and technical communication, he will clerk at the Supreme
Court of Texas before practicing in the Orange County, California office of Gibson,
Dunn & Crutcher. He would like to thank Ron Woessner at ZixCorp for the opportunity
to do this research.
1
Greg Critser, One Nation, Under Pills, L.A. TIMES, Dec. 15, 2002, at M.6, available at
http://www.namiscc.org/News/2003/Winter/PharmaceuticalStatistics.htm.
2
Id.
3
Id.
4
See, e.g., Ronald L. Scott, Cybermedicine and Virtual Pharmacies, 103 W. VA. L. REV.
407, 410-11, 421 & 482-83 (2001).
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coverage of prescription drugs for senior citizens. 5 On the business front,
the issue most in the news is the high cost of brand-name pharmaceuticals
compared to generics, and the high profit margin of pharmaceutical
companies. 6
[2] Another issue that does not receive the same headlines but has an
enormous impact upon the delivery of health care is the increasing
incorporation of high technology into the writing of prescriptions, more
commonly referred to as electronic prescribing, or e-prescribing. The
nation’s 473,000 office-based physicians write the bulk of those 3.1 billion
prescriptions, which somehow need to get from the physician to the
pharmacy. 7 Increasingly, more and more physicians are choosing to
transmit their prescriptions electronically.8 Numerous e-prescribing
system providers ranging from A (A4 Health Systems) to Z (ZixCorp)
have fueled this growth, including SureScripts, which certifies retail
pharmacies for receipt of transmissions and functions as a sort of technical
distributor for e-prescribing. 9 Despite initial implementation costs, eprescribing has the potential to reduce health care costs by improving
efficiency, security, and patient safety. 10
[3] Although much potential exists, the legal environment within this field
presents numerous challenges. The first of these challenges is the
inconsistency in regulatory schemes. The transmission of prescriptions is
regulated by state law, and there are currently fifty different approaches,
5

Medicare Prescription Drug, Improvement, and Modernization Act of 2003, 42
U.S.C.A. § 1395w-101 (Sup. 2005).
6
See, e.g., Thomas B. Leary, Antitrust Issues in the Settlement of Pharmaceutical Patent
Disputes, Part II, 34 J. HEALTH L. 657, 661 (2001).
7
See Joseph Goedert, Electronic Prescribing: Is It Just What the Doctor Ordered?,
HEALTH DATA MGMT., June 2002, available at
http://www.healthdatamanagement.com/HDMSearchResultsDetails.cfm?DID=12100.
8
Compare id. (writing that e-prescribing increased from two to four percent of physicians
in 2000 to six percent in 2001), with Ken Terry, Expanding Clinical Connections:
Prescriptions, MED. ECON., Oct. 8, 2004, available at
http://www.memag.com/memag/article/articleDetail.jsp?id=127292 (claiming that, by
2004, e-prescribing was as high as eighteen percent).
9
SureScripts, About SureScripts, http://www.surescripts.cm/coBack.htm (last visited
April 5, 2006).
10
E.g., Michelle Stowell, Transmitting Prescriptions Electronically: A Benefit or a
Burden?, 32 MCGEORGE L. REV. 742, 750 (2001); Terry, supra note 8.
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ranging from a lack of recognition of e-prescriptions to language that
specifies technical standards and tries to accommodate trends. 11 Because
controlled substances are regulated by the Drug Enforcement
Administration, federal law transcends state. 12 Unfortunately, the DEA
has not yet promulgated regulations for e-prescribing, so the states differ
in their interpretation of the acceptability of electronic transmission of
prescriptions for controlled substances. 13 This uncertainty is heightened
by the legislative process and regulatory language, neither of which can
adequately account for the rapid evolution of the technologies involved in
e-prescribing. 14 Even political pressures come into play, such as the
requirement in the Medicare Modernization Act for an e-prescribing
technical standard by 2008. 15
[4] These legal issues are a pressing concern as e-prescribing emerges as
an increasingly important part of health care. Attorneys for the companies
that create and maintain these systems, for the doctors and pharmacists
who use these systems, for the agencies that regulate these systems, and
for the managed care and insurance providers that can reduce costs with
these systems must stay abreast of a legal environment framed by
uncertainty, conflict, and rapid change. Although some recent legal
scholarship has dealt with e-prescribing, the focus has been on the impact
to federal law, such as HIPAA and E-Sign, or on practices that violate
existing laws, such as ordering drugs without a prescription via the

11

Compare 49 PA. CODE § 27.20 (2005) (allowing for facsimile transmission of
prescriptions but making no mention of electronically-generated prescriptions), with 105
MASS. CODE REGS. 721.030 (2004) (providing precise standards for electronic technical
security and e-signatures and accommodating potential changes to federal law regarding
controlled substances).
12
See 21 C.F.R. §§ 1300 – 1316 (2005).
13
Compare 22 TEX. ADMIN. CODE § 291.34(b)(4) (2004) (allowing Schedule III-V
substances to be transmitted electronically), with Memorandum from William Black,
Wis. Dep’t of Reg. & Licensing, to Wis. Pharmacy Examining Bd. (Mar. 16, 2004),
available at http://drl.wi.gov/boards/phm/pap/RXSignatures3-16-04.pdf (last visited
January 8, 2005) (interpreting federal regulations as requiring electronically-generated
prescriptions for Schedule III-V substances to be received via facsimile equipment and
then orally verified with the prescriber).
14
Marsha N. Cohen, RX by Email—Bad Medicine for a Chronic Rulemaking Illness,
ADMIN. & REG. L. NEWS 10, 11 (Fall 2003).
15
42 U.S.C.A. § 1395w-104(e) (Supp. 2005).
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Internet. 16 As Ridgely and Greenberg point out in their article, however,
those who undertake e-prescribing ventures must understand statutes and
regulations that vary widely from state to state. 17 This essay will explore
the e-prescribing laws of the three most populous states: California,
Texas, and New York, as well as the DEA regulations that overlay state
law to uncover the most typical legal problems encountered with the
implementation and use of e-prescribing systems. It will then offer ways
to avoid, account for, or even change these problems. First, though, it will
examine e-prescribing in general and the impact of e-prescribing systems.

II. E-PRESCRIBING IN GENERAL
A. TRADITIONAL VERSUS E-PRESCRIBING
Traditional Prescription Methods and Their Drawbacks
[5] Most people are familiar with the traditional methods for getting and
filling a prescription. A patient must first visit a physician, who after an
examination determines whether certain medications are necessary for
treatment. The physician then writes the medication order on a
prescription pad for the patient to deliver to the pharmacy, or the physician
personally phones the order into the pharmacy or, in more recent times,
sends it by facsimile. 18 The patient then visits the pharmacy, either to pick
up an order sent by phone or fax, or to present the prescription form to a
pharmacist for filling.
[6] These traditional methods present several problems. First, they are
inefficient because of time wasted transcribing information for oral orders,
re-entering data required for state and federal reporting, and calling

16

M. Susan Ridgely & Michael D. Greenberg, Pharmacy, Facsimile, and Cyberspace:
An Examination of Legal Frameworks for Electronic Prescribing, 13 ALB. L.J. SCI. &
TECH. 1 (2002); Scott, supra note 4.
17
Ridgely & Greenberg, supra note 16, at 40-41.
18
In many states, prescriptions for some controlled substances require a special form
printed and distributed by the state for security and tracking purposes. See, e.g., N.Y.
PUB. HEALTH LAW § 3332(2) (Consol. 2005); CAL. HEALTH & SAFETY CODE § 11161.5
(West 2005).
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doctors to clarify illegible handwriting. 19 This inefficiency increases the
labor costs for both doctors’ offices and pharmacies. 20 It also wastes the
patient’s time because of the delay between presenting and filling a
written order. 21 Other major concerns about traditional methods include
potential medication errors due to illegible handwriting, the need to
transcribe prescriptions multiple times, and possible adverse drug
interactions. 22 Medication errors arising from the traditional methods of
prescribing medication lead not only to wasted time and extra hospital
visits, they cause an estimated 7,000 deaths annually. 23
E-Prescribing and Its Perceived Drawbacks
[7] E-prescribing is “the use of an automated data entry system to
generate a prescription, rather than writing it on paper.” 24 In many ways,
the core process is the same: the patient visits a physician, who, following
an examination, determines if medications are necessary for treatment, and
then writes a prescription. 25 The key difference is the manner of
transmitting the prescription: in e-prescription, the physician generates the
prescription using a computer or a hand-held device such as a Blackberry,
then transmits the prescription to an appropriate pharmacy. Several
companies offer software and related services that allow physicians to eprescribe by, for example, using a stylus or mouse to point and click his or
her way through the patient’s record and to select the appropriate
19

Stowell, supra note 10, at 747.
One doctor estimated that by switching from traditional methods to e-prescribing, his
practice saved at least fifteen minutes of nurse overtime per day, and daily calls from
pharmacies dropped from twenty to two, which translated to about $11,000 in one year.
Terry, supra note 8.
21
Stowell, supra note 10, at 747.
22
Id.
23
Id. at 742.
24
Ridgely & Greenberg, supra note 16, at 3 (quoting Peter Kilbridge, E-Prescribing, IHEALTH REPORTS 5, Nov. 2001,
http://www.chcf.org/documents/ihealth/Eprescribing.pdf).
25
E-Prescribing could provide a means for obtaining and filling prescriptions without any
patient-doctor face-to-face interaction. Barbara J. Williams, On-Line Prescriptions and
Drug Sales: An Overview of Emerging Issues, 1 HOUS. J. HEALTH L. & POL'Y 147, 147–
48 (2001). However, many states explicitly forbid dispensing drugs based on a
prescription where no valid patient-physician relationship exists, such as when the only
interaction has been via the Internet. See, e.g., 22 TEX. ADMIN. CODE § 291.34 (b)(1)(B)
(LEXIS 2004).
20
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medication. 26 After the doctor generates an electronic prescription, eprescription software routes the prescription through the provider’s secure
server to the pharmacy (and even the patient’s insurance provider, if so
desired), where the prescription arrives as either electronic data or as a
printed fax. 27 In this way, e-prescription software is able to automatically
create and store electronic records for the physician, the pharmacy, and
even the insurance provider. 28
[8] As with any new technology, there are some concerns about the
limitations and shortcomings of e-prescription technology. For example,
electronic systems that transmit data over the Internet are susceptible to
interference by computer hackers. 29 One possible consequence of hacker
interference is diversion, whereby hackers use the system to illegally
acquire prescription drugs by simulating authentic prescriptions. 30
Another possible consequence is access to confidential information. Since
patient data accompanies the e-prescription, patients could be less likely to
provide their physicians with important private information for fear of it
being intercepted by hackers. 31 Another concern about e-prescriptions is
that these electronic systems will be inefficient since pharmacists may be
required to reduce to writing all electronically transmitted prescriptions for
record-keeping purposes. 32 Finally, high technology often means high
cost, and not only do e-prescription systems require start-up costs and
26

Aside from companies such as Allscripts and ZixCorp, which are major providers of eprescription software and services, at least twenty-five different companies and
organizations have some type of e-prescribing system. SureScripts, supra note 9.
27
See, e.g., Kilbridge, supra note 24, at 10. For pharmacies that have neither fax nor
electronic capability, the physician’s office could simply print the prescription for the
patient, who then takes the script to the pharmacy in person.
28
The various e-prescribing system providers’ websites provide more thorough
descriptions of this process. See, e.g., PocketScript, ZixCorp,
http://www.zixcorp.com/caredel/eprescribing.php (last visited Jan. 17, 2006).
29
In an attempt to thwart hackers, one e-prescription service has licensed biometrics
technology to ensure that the user of its e-prescription service is a licensed physician or
pharmacist. Steve Gold, Site Employs Biometrics for E-Prescription Security,
COMPUTERUSER.COM, Apr. 18, 2000,
http://www.computeruser.com/news/00/04/18/news6.html.
30
Stowell, supra note 10, at 743, 748.
31
Id. at 749. Of course, hacker access to a patient’s personal information creates the
potential for identity theft.
32
Id. at 746. Some states require pharmacies to maintain hard copies of prescriptions for
a specific amount of time for, among other reasons, law enforcement. Id.
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ongoing service fees for physicians and pharmacies, but also state officials
may experience increased regulatory and enforcement costs. 33
B. THE BENEFITS OF E-PRESCRIBING FAR OUTWEIGH THE
DRAWBACKS
[9] These fears may have seemed reasonable a decade ago, but
advancements in technology and changes in the law have rendered them
virtually null. E-prescribing is not only more secure than traditional
methods, it can increase efficiency and lower costs. 34 Although the
benefits are separated for convenience, note that they actually interrelate.
For example, improved efficiency leads to lower physician and pharmacy
costs and to fewer patient medical errors; fewer medical errors leads to
reduced insurance costs as well as less medical provider liability.
Increased Security
[10] Two changes have made e-prescribing more secure than traditional
methods regarding patient confidentiality and diversion. First, anyone
who handles patient information—health care professionals, e-prescribing
system providers, and insurance companies—must now meet HIPAA
standards for confidentiality and security. 35 Second, improvements in
technology—such as minimum 128-bit encryption, passwords to log in to
the systems, and automatic log-outs for periods of inactivity—have made
interception more difficult and therefore less likely. 36 Although dedicated
hackers can still intercept electronic data, consider that thieves can more
easily steal and forge prescription pads. 37

33

Id.
See EHEALTH INITIATIVE, ELECTRONIC PRESCRIBING: TOWARD MAXIMUM VALUE AND
RAPID ADOPTION 73-74 (2004),
http://www.ehealthinitiative.org/assets/documents/eHIFullReportElectronicPrescribing2004.pdf.
35
Health Insurance Portability & Accountability Act of 1996, Pub. L. No. 104-191, 110
Stat. 1936 (codified as amended in scattered sections of 45 C.F.R.).
36
See PocketScript, supra note 28.
37
EHEALTH INITIATIVE, supra note 34, at 73.
34
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Better Patient Care
[11] E-prescribing can improve the effectiveness of health care by
reducing errors. For example, the elimination of hand-written
prescriptions and transcriptions by office staff reduces errors caused by
illegible writing or incorrect transcribing. 38 Also, e-prescribing systems
allow easy access to patient records and to computerized drug formularies,
and they display warnings to the physician about patient allergies and
adverse drug interactions. 39 These factors can significantly reduce the
estimated 2.1 million adverse drug events that lead to 190,000
hospitalizations and thousands of deaths each year. 40
Greater Efficiency and Reduced Costs for Physicians and Pharmacists
[12] This decrease in medication errors is the result of an increase in
efficiency. E-prescribing increases efficiency because the data needs to be
entered only once, eliminating transcriptions by nursing and secretarial
staff and reducing the need for call backs since nothing is handwritten. 41
Further, the pharmacy can fill the order before the patient arrives, saving
the patient time. 42 Because the information is already stored
electronically, refills are easier for all parties involved. 43
[13] This increase in efficiency means a reduction in labor and costs for
physician offices and pharmacies. For example, reductions in callbacks
from pharmacies saved one four-doctor office about $11,000 in overtime
pay to nurses in one year. 44 Fewer call-backs, the elimination of
transcriptions, and shortened refill times saved one eight-doctor office
about 3,000 total hours in one year. 45 Even with initial start-up costs and

38

Stowell, supra note 19 at 747.
Terry, supra note 8.
40
EHEALTH INITIATIVE, supra note 34, at 28.
41
Stowell, supra note 19 at 747.
42
Id.
43
Terry, supra note 8.
44
Id.
45
Jack Beaudoin, Study: E-Prescribing Cuts Labor Costs by 50 Percent, HEALTHCARE IT
NEWS, Sept. 7, 2004,
http://www.healthcareitnews.com/NewsArticleView.aspx?ContentID=1464.
39
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ongoing service charges, e-prescribing systems could pay for themselves
in less than a year. 46
[14] Finally, e-prescribing offers a partial solution in the debate over tort
reform and medical malpractice insurance. Two percent of all adverse
events lead to the filing of a medical malpractice claim, and the more
severe the damage, the more likely a claim. 47 E-prescribing could
therefore eliminate up to 4,000 claims per year, easing the burden on
health care providers, insurers, and the courts. 48
The Business Impact of E-Prescribing
[15] Currently, physicians write 3.1 billion prescriptions annually, which
is more than ten for each American. 49 Many of these prescriptions are
made in hospital, hospice, and institutional settings, although
approximately 473,000 physicians work in private office settings and
could make use of e-prescribing systems. 50 Only five to eighteen percent
of these physicians currently use e-prescribing, so a huge growth potential
exists. 51
[16] The start-up costs average approximately $2,000 per physician in the
first year, and much less thereafter. 52 This average accounts for
implementation and software fees from the service provider, hardware
such as the handheld device, wireless connectivity in the office, and data
carrier fees. 53 After initial installation, the physician must pay ongoing
software and support fees to the e-prescribing service provider. 54

46

Terry, supra note 8.
David A. Hyman, Medical Malpractice and the Tort System: What Do We Know and
What (If Anything) Should We Do about It? 80 TEX. L. REV. 1639, 1643 (2002).
48
Id.; see EHEALTH INITIATIVE, supra note 34, at 28.
49
Critser, supra note 1.
50
Goedert, supra note 7.
51
Terry, supra note 8.
52
Id.
53
Id.
54
Id.
47
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[17] Despite these costs, health insurers, encouraged by the federal
government, have begun to promote e-prescribing. 55 For example,
WellPoint has dedicated $40 million to provide hardware and a one-year
subscription to either Allscripts or ZixCorp for its 19,000 network
physicians, and both Blue Cross Blue Shield of Massachusetts and Tufts
Health Plan offer a free, one-year subscription to PocketScript for 3,400
high-prescribing physicians. 56
[18] Health plans promote e-prescribing for one simple reason: the
potential long-term savings far outweigh costs. Increased patient safety
adds to a healthier bottom line. Cutting the 190,000 hospitalizations that
result annually from the 2.1 million adverse drug events could equal a
savings of between $39 and $79 per employee per year in employer health
plans. 57 These numbers do not even address the savings for medical
malpractice insurers because of the reduction in tort liability. Although
these figures do come from studies sponsored by the e-health industry and
should be viewed guardedly, the truth is that more physicians are using eprescribing, more health plans are promoting e-prescribing, and more state
laws are changing to accommodate e-prescribing.
III.

THE LEGAL ENVIRONMENT FOR E-PRESCRIBING
A. DEA REGULATIONS

[19] The federal government regulates controlled substances through the
Drug Enforcement Agency (DEA). 58 Substances are listed as controlled
because of their potential for abuse or addiction.59 Controlled substances
are further classified by the DEA into five schedules, which are based on
their medicinal value, potential for abuse, and safety or dependence
liability. 60 Schedule I substances (LSD, mescaline, marijuana) have no
55

Id.
Id.
57
EHEALTH INITIATIVE, supra note 34.
58
See 21 C.F.R. §§ 1300 – 1316 (2005).
59
21 U.S.C. § 802(6) (2000).
60
Prescription Drugs, State Monitoring Programs May Help to Reduce Illegal
Diversion: Testimony Before the Subcomm. on Health, Comm. on Energy and Commerce,
108th Cong. 4 (2004) (statement of Marcia Crosse, Director, Public Health and Military
Health Care Issues).
56
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acceptable medical use and therefore may not be prescribed. 61 Schedule II
substances (Ritalin, Demerol, opiates) have medical uses but an extremely
high potential for abuse. 62 Prescriptions for Schedule II substances are the
most restricted: they must be written (except for emergencies) and
manually signed, the dosage is limited, and most of them cannot be
refilled without a new prescription. 63 Schedule III-V substances (anabolic
steroids, anti-anxiety medications, narcotic cough syrups) have less
potential for abuse. 64 Prescriptions for these substances may be oral or
written and manually signed, and they may be refilled for up to six
months. 65 Pharmacies must maintain records for all controlled substances
dispensed and report these to the DEA on a regular basis. 66 These federal
regulations are the minimum standards that all states must follow.
Although the DEA has no explicit regulations for electronic transmission,
it currently treats e-prescriptions as oral prescriptions, so that Schedule IIIV substances may be transmitted electronically as long as the pharmacist
verifies the prescription. 67
B. CALIFORNIA
[20] California regulates e-prescribing and is one of the most e-friendly
states because it has few specific limitations. State regulations establish
the requirements for the content of an e-prescription. 68 California has no
explicit technical requirements. Instead, the state has an open-ended
definition of e-prescriptions that allows for different and emerging
technologies. 69 The content requirements for controlled substances are in
a different code section but essentially the same. 70 California even has a
code provision that would allow for the electronic transmission of
61

Id.; See 21 C.F.R. § 1308.11 (2005).
Crosse, supra note 60; see § 13.08.12.
63
Crosse, supra note 60; see § 1306.11.
64
Crosse, supra note 60; see §§ 1308.13 – 1308.15.
65
Crosse, supra note 60; see § 1306.21.
66
Crosse, supra note 60; see §§ 1304.01 – 1304.33.
67
Cohen, supra note 14.
68
CAL. CODE REGS. tit. 16, § 1717.4 (Westlaw through 2005).
69
Id.; see CAL. BUS. & PROF. CODE § 4040(a), (c) (West 2005) (defining an electronic
data transmission prescription as “any prescription order, other than an electronic image
transmission prescription, that is electronically transmitted from a licensed prescriber to a
pharmacy”).
70
CAL. HEALTH & SAFETY CODE § 11164(b)(1), (3) (West 2005).
62
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Schedule II substances if and when the DEA regulations change. 71
Although state law allows pharmacists to substitute a generic for a
prescribed brand-name drug, physicians may prevent such substitution on
an e-prescription. 72 Finally, out-of-state physicians may e-prescribe as
long as they are licensed in their home state. 73
C. TEXAS
[21] Texas also allows for e-prescribing, although its approach differs
from California because Texas has more extensive and explicit
regulations. For example, Texas has thirteen different content
requirements for e-prescriptions, including a statement that the
prescription is “electronically transmitted to:” the recipient. 74 The
regulations for controlled substances are the same as for non-controlled. 75
Technical requirements are also listed, though no technical standards are
specified. Thus, for e-prescriptions, data must not be altered during
transmission, and confidential patient information must be kept in
accordance with federal and state law, but the means for achieving these
two requirements are not given. 76 Physicians may prevent generic
substitution using e-prescribing. 77 If the brand drug is medically
necessary and the patient will receive Medicaid reimbursement, however,
the physician must provide a written prescription order within thirty
days. 78 E-prescriptions from out-of-state physicians are acceptable, but
for controlled substances, the out-of-state physician must be registered
under the Texas Controlled Substances Act. 79

71

Id. § 11164.5(a).
CAL. BUS. & PROF. CODE § 4073(a), (b) (West 2005).
73
CAL. HEALTH & SAFETY CODE § 11150 (West 2005); CAL. BUS. & PROF. CODE § 4005
(West 2005).
74
22 TEX. ADMIN. CODE § 291.34(b)(6)(B)(ix) (West 2005).
75
See id. § 291.34(b)(6)(B)(iii).
76
Id. § 291.34(b)(4)(A)(ii)(I)-(II).
77
Id. § 309.3(c)(3)(A)-(C).
78
Id. § 309.3(c)(3)(C).
79
Id. § 291.34(b)(4)(C)(ii).
72
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D. NEW YORK
[22] New York has the least progressive and most confusing eprescription regulations of the three states, although changes are pending.
New York allows e-prescriptions, except for controlled substances, which
are not allowed but not expressly prohibited. 80 E-prescriptions must meet
three technical requirements: an electronic signature; electronic encryption
that will prevent access, alteration or use by an unauthorized person; and
the ability to be reproduced in hard copy by the pharmacist. 81 Further, the
State Board of Pharmacy requires that e-prescribing systems have
passwords, PINs, or other authentication of the prescriber. 82 Regarding
generic substitution, the prescription form must contain the words “THIS
PRESCRIPTION WILL BE FILLED GENERICALLY UNLESS
PRESCRIBER WRITES ‘d a w’ IN THE BOX BELOW,” as well as meet
other font, placement, and design requirements. 83 Thus, the initials “d a
w” (“dispense as written”) must be handwritten, which is of course
impossible electronically. 84 For Medicaid patients, the state further
requires that the physician handwrite “brand medically necessary” or
“brand necessary” in addition to “d a w.” 85 Finally, the laws themselves
are difficult to track and decipher. Not only must an attorney consult
various code titles, he or she must also refer to the Education statutes for
the generic substitution requirement.
[23] Recently enacted legislation should make e-prescriptions more
feasible in the near future. New York has redefined “prescription” to
include electronic prescriptions in the context of controlled substances. 86
Also, the state legislature has empowered the Commissioner of Health to

80

N.Y. COMP. CODES R. & REGS. tit. 8, § 63.6(a)(7)(i) (Westlaw through 2005); see N.Y.
State Educ. Dep’t Office of the Professions, Electronic Transmittal of Prescriptions:
Questions & Answers ¶ 14, http://www.op.nysed.gov/pharmqa.htm (last visited Nov. 7,
2005).
81
N. Y. COMP. CODES R. & REGS. tit. 8, § 63.6(a)(7)(ii)(a)-(c) (Westlaw through 2005).
82
See N.Y. State Educ. Dep’t Office of the Professions, supra note 70 at ¶ 6.
83
N.Y. EDUC. LAW § 6810(6)(a) (Consol. 2005).
84
Id.
85
N.Y. SOC. SERV. LAW § 361-a(9)(c) (Consol. 2005).
86
N.Y. PUB. HEALTH LAW § 3302(31) (Consol. 2005).
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create regulations regarding the use and transmission of e-prescriptions,
including changes for Medicaid patients and out-of-state physicians. 87
IV. PROBLEMS AND CHALLENGES FOR E-PRESCRIBING
[24] As this sample of regulations demonstrates, much variation exists in
the limits of e-prescribing in a given state. Even where allowed,
restrictions on form and content could cause an e-prescribing system that
is valid in one state to be invalid in another. Affecting all of this is
uncertainty about the limits of e-prescribing controlled substances under
federal regulations. The following are the most common problems that
attorneys in health care fields encounter.
A. THE LACK OF FEDERAL STANDARDS
The Questionable Permissibility of E-Prescribing for Controlled
Substances
[25] Many commonly prescribed drugs are controlled substances: antianxiety medications like Ativan, sleep aids like Ambien, the attentiondeficit disorder medication Ritalin, even cough syrup with codeine. 88 For
maximum efficiency, therefore, most health care professionals want eprescribing laws to allow for transmission of these substances. 89
Currently, the DEA, which has ultimate authority over all controlled
substances, has promulgated no regulations regarding e-prescribing. The
DEA is still conducting a pilot program using digital signatures and Public
Key Infrastructure (PKI) technology, which, although initiated in 1999,
has yet to result in regulation. 90
[26] In the meantime, the DEA has chosen to treat e-prescriptions of
controlled substances as oral orders. 91 This position has not been posted
87

Id. §§ 21, 3308(5)-(6).
21 C.F.R. § 1308.12 – 1308.15 (2005).
89
See Cohen, supra note 14, at 10.
90
DEA Diversion Control Program, Electronic Transmission of Prescriptions: Electronic
Order Forms, http://www.deadiversion.usdoj.gov/ecomm/e_ordrs/ (last visited Jan. 16,
2006).
91
See SureScripts, SureScripts Partner & Provider Issue Bulletin #1: Transmission
Methods Approved by the Drug Enforcement Administration (DEA) for Controlled
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as official policy, which continues to be that e-prescriptions of controlled
substances are not valid. 92 Rather, a 2002 letter from the Chief of the
Liaison and Policy Section of the Office of Diversion Control to a maker
of e-prescribing systems explaining this position has circulated widely, so
that many state regulators and health care professionals assume that eprescriptions for controlled substances are acceptable under federal law. 93
Marsha Cohen calls this informal law process a response to “regulatory
ossification,” which basically means that the official lawmaking process
has not kept pace with technology and industry. 94 Although she favors eprescriptions, Cohen has criticized this response because it is outside of
the notice and comment rulemaking process. 95 Attorneys are put in the
awkward position of giving legal advice that is correct based upon
informal regulatory practice but that could become incorrect when the
official regulations are approved—creating problems for all e-prescribing
system providers, the health care professionals who use them, and even
state officials who may need to rewrite their regulations.
[27] These federal regulations are also problematic because they merely
represent the minimum standard, so most states can and do have their own
controlled substances regulations that are more restrictive. 96 Often, the
regulations that flow from these state controlled substance statutes
incorporate federal law. 97 On a theoretical level, if the minimum
standards are hazy and inexact, then states are building on a flawed
foundation. Further, and of more immediate concern for attorneys, is the
inconsistency because of states’ differing interpretations of the minimal
federal standard. 98
Substance Prescriptions, http://www.surescripts.com/DEADocument.doc (last visited Jan.
16, 2006). This approach defeats one of the primary purposes of e-prescribing: efficiency.
Oral orders for controlled substances must be personally verified by the pharmacist. This
means that upon receipt of an e-prescription, the pharmacist must call the physician’s
office, even though the prescription has gone through an encrypted and passwordprotected system.
92
Cohen, supra note 14, at 10-11.
93
Id. at 11.
94
Cohen, supra note 14, at 11.
95
Id.
96
See, e.g., CAL. HEALTH & SAFETY CODE § 11164.5(a) (West 2005).
97
Id.
98
Compare 22 TEX. ADMIN. CODE § 291.34(b)(4) (2004) (allowing Schedule III-V
substances to be transmitted electronically), with Black, supra note 13 (interpreting
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Technical Inconsistency
[28] A second problem flowing from federal law relates to technology.
Although current e-prescribing systems use Electronic Data Interchange
(EDI), which features password-protected access and routes data through
secure servers, the DEA’s test program incorporates Public Key
Infrastructure (PKI) technology and digital signatures. 99 With PKI, data is
transmitted as complex computer algorithms, the recipient of the data must
have both a public and a private “key” to decode the data, and third-party
Certification Authorities issue and maintain the keys. 100 Although PKI
theoretically offers higher levels of security, privacy, authentication, and
non-repudiation than EDI, practically these benefits are nullified by the
high cost and difficulty in implementing and maintaining the technology.
The result has been that the high expectations of PKI in the 1990s have
failed to materialize in this decade. 101
[29] If the DEA adopts this technical standard, then it would pre-empt
laws like those in Texas. 102 Although the California controlled substance
e-prescribing statute includes language that accommodates changes in
federal law, such changes would still require state approval of systems. 103
Either way, a change in the technical standard at the federal level would
invalidate existing systems—costing e-prescribing providers and the
health care professionals who have already adopted this technology much
expense—and require a more expensive and difficult-to-use technology,
without adding any appreciable benefit.

federal regulations as requiring electronically-generated prescriptions for Schedule III-V
substances to be received via facsimile equipment and then orally verified with the
prescriber).
99
DEA Diversion Control Program, supra note 90.
100
See Jan Lavorn, The Power of PKI, HEALTH MGMT. TECH. 20 (Dec. 2001).
101
Even PKI providers and advocates acknowledge these limitations. See ANGELA
KEITH, SANS INSTITUTE, COMMON ISSUES IN PKI IMPLEMENTATIONS—CLIMBING THE
“SLOPE OF ENLIGHTENMENT” (2003),
http://www.giac.org/practical/GSEC/Angela_Keith_GSEC.pdf.
102
22 TEX. ADMIN. CODE § 291.34(b)(4) (2004) (treating e-prescriptions for controlled
substances as oral prescriptions and therefore requiring no signature).
103
CAL. HEALTH & SAFETY CODE § 11164.5(a) (West 2005).
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[30] A further federal complication is the requirement in the Medicare
Modernization Act for a national technical standard by 2009, at least for
transmission related to Medicare. 104 Because the DEA is under the
Department of Justice and Medicare is under the Department of Health
and Human Services, there could be different, even conflicting, standards.
Such pending changes, which are years from being finalized, create
problems for health care attorneys who must make business and regulatory
decisions now.
B. STATE STATUTES & REGULATIONS
A Time of Flux
[31] Perhaps the most important issue regarding state laws is how quickly
they change. Although these changes usually work to the benefit of eprescribing, attorneys who need to give advice based upon the current law
face problems when a bill to overhaul e-prescribing is pending in the state
legislature, or when a new version of the law will take effect in three
months. Consider that, when I first drafted this essay in January 2005, a
change in New York laws to allow e-prescriptions for Medicaid recipients
did not take effect until April. 105 This ongoing flux is the norm in most
states. For example, the Texas requirement that generic substitution could
only be prevented by handwriting “brand medically necessary” was
changed in 2002. 106 Also, the main California e-prescribing statute had
slight numbering and textual changes that took effect January 1, 2005. 107
Finally, e-prescribing stakeholders in New York must sit and wait while
the state promulgates regulations regarding controlled substances,
Medicaid, and out-of-state prescribers. 108 \
Attention to Details
[32] Attorneys can easily spot major differences among state statutes and
regulations, such as whether a state even allows e-prescriptions of
104

42 U.S.C.A. § 1395w-104(e) (Supp. 2005).
N.Y. COMP. CODES R. & REGS. tit. 18, § 505.3(b)(5) (2004).
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22 TEX. ADMIN. CODE § 309.3(c)(3)(A) (2004).
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CAL. HEALTH & SAFETY CODE § 11164 (West 2005).
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N.Y. PUB. HEALTH LAW §§ 21, 3308(5) (McKinney Supp. 2005); N.Y. EDUC. LAW §
6810 (McKinney Supp. 2005).
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controlled substances. Often, however, more subtle legal requirements
can escape notice. For example, Texas requires that e-prescriptions
contain a statement such as “electronically transmitted to:” and the name
of the receiving pharmacy. 109 Also, Texas requires the “electronic access
number” of the pharmacy to which the prescription is transmitted, yet it
does not define this term. 110 It probably means the telephone number for
faxes or computer address for EDI, but it may be something else, such as a
state-provided account number. Failure to include either one of these
could invalidate the entire prescription, or at the least require time-wasting
call-backs for verification. Many states have variations on these
requirements.
Inconsistency with the Electronic Medium
[33] State laws are often incompatible with e-prescribing. For example,
because the state itself must pay the higher cost of brand-name drugs for
Medicaid patients, states often have strict guidelines for how a physician
can prevent substitution from the brand name drug to a generic equivalent.
In Texas, a physician may prevent substitution via an e-prescription, but
within thirty days he or she must provide a written prescription drug
order. 111 This requirement means a second prescription, thus negating the
efficiency goal of e-prescribing.
Inconsistency from State to State
[34] Several states have large metropolitan areas that spill into other
states, such as Portland, St. Louis, New York City, and even Texarkana,
which has a total population well in excess of 100,000. 112 A person who
lives in one state but works in the other could easily have a physician in
one state but a pharmacy in the other. A requirement that out-of-state
physicians register under the Texas Controlled Substances Act for their
controlled substance prescriptions to be valid is a nuisance. 113 The fact
109

22 TEX. ADMIN. CODE § 291.34(b)(6)(B)(ix) (2004).
Id. § 291.34(b)(6)(B)(x).
111
22 TEX. ADMIN. CODE § 309.3(c)(3)(A)-(C) (2004).
112
Real Estate Center at Texas A&M, Texarkana Market Overview 2001: Population,
2002, http://recenter.tamu.edu/mreports01/texarkana1.html (referencing the U.S. Census
Bureau).
113
22 TEX. ADMIN. CODE § 291.34(b)(4)(C)(ii) (2004).
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that New Jersey requires an official state prescription form or oral
verification for controlled substances, New York is currently promulgating
regulations for controlled substances, and Connecticut requires state
approval of e-prescribing systems while it promulgates new regulations is
a legal migraine. 114
V. SOLUTIONS
A. RECOMMENDATIONS
[35] The problems outlined in the previous section make addressing legal
concerns, whether in giving advice to a practitioner or providing eprescribing services that will be valid in every state, incredibly difficult,
but not impossible. Some approaches can help ease the problems.
Aim at Maximum Inclusion
[36] E-prescribing system providers can overcome the myriad of specific
state requirements by incorporating as many as possible. For example, the
requirement in Texas that the prescription be marked as electronically
transmitted appears in several other states’ regulations.115 Nothing in the
regulations of states that do not have this requirement, however, forbids
including the information. Creating a system that makes this electronic
transmission tag part of every prescription in every state will therefore
ensure that such requirements are met.
Track Legislative and Regulatory Changes
[37] Many state Boards of Pharmacy provide listserv notices or post
online newsletters. 116 These services give information about proposed
114

Compare N.J. ADMIN. CODE 13, § 13:35-7.4A(h) (2004), with N.Y. PUB. HEALTH
LAW § 3308(5) (McKinney Supp. 2005), and CONN. GEN. STAT. ANN. § 20-614(d)(3)
(West 2004 ).
115
22 TEX. ADMIN. CODE § 291.34(b)(6)(B)(ix) (2004); see, e.g., CONN. AGENCIES
REGS. § 20-576-41 (2004).
116
E.g., Bd. of Pharmacy, Join or Leave the Board of Pharmacy's E-Mail Notification
List, http://www.pharmacy.ca.gov/subscriber_page.htm (last visited Jan. 16, 2006); Tex.
State Bd. of Pharmacy, Newsletter,
http://www.tsbp.state.tx.us/newsletter/NewsletterStart.htm (last visited Jan. 16, 2006).
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legislative and regulatory changes, Board meeting times and places, and
Q&A sections that clarify how certain regulations are defined and
enforced. 117 Also, regulatory officials in some states are excellent about
returning phone calls and responding to emails. 118 Finally, West’s
KeyCite allows attorneys to select particular state statutes—and for larger
states their regulations—for notification of changes. 119
Realize Where the Responsibility Lies
[38] Many states place the responsibility for ensuring the security and
validity of an electronic prescription on the physician who transmits and /
or the pharmacist who will fill and dispense the medication. 120 Attorneys
for health care providers should advise their clients of particular state
restrictions or pending changes, while attorneys for e-prescribing system
providers should strive for maximum functionality, trusting that health
care professionals will follow state law. In other words, the systems
themselves should accommodate the most progressive state laws, and
health care professionals should know the limit of their particular states’
regulations and use only those features which are appropriate.
Drive the Regulations Rather than Being Driven
[39] Although changes in the law seem like a problem, the process of
change may actually provide the best solution because it allows an
opportunity for action. State governments allow for comment on proposed
regulatory changes. For states with restrictive regulations, contact state
legislators and the Board of Pharmacy directly. Smaller states should
realize that manufacturers are targeting larger states and adopt regulations
that follow the trends in larger states. 121 As discussed above, the trend in
California, Texas and New York is toward more favorable e-prescribing
laws.
117

E.g., Tx. State Bd. of Pharmacy, supra note 116.
E.g., Telephone Interview with William Black, Legal Counsel, Wis. Dep’t of Regulation
& Licensing (June 30, 2004).
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[40] Driving the federal process may be most important. Both the DEA
and Medicare are promulgating standards, which state regulations will
have to accommodate. Both provide for comment and feedback, so
attorneys and state regulators interested in e-prescribing should take
advantage. 122
VI. CONCLUSION
[41] Because of improvements in efficiency and patient safety, eprescribing should continue to expand. This expansion includes dozens of
e-prescribing system providers, regulatory agencies from all fifty states,
and every managed care and insurance provider. It affects hundreds of
thousands of health care professionals, and it will mean billions of dollars
both in costs to implement and maintain and in savings from efficiency
and safety. The non-business side means reduced, or even eliminated,
adverse drug reactions, which means fewer hospitalizations and deaths,
which leads to better patient care. Attorneys in health care fields will be
challenged to stay abreast of a rapidly changing legal environment as state
and federal laws develop to accommodate this technology.
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Infrastructure Enabled Controlled Substance Orders, 67 Fed. Reg. 1,507 (Jan. 11, 2002);
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